摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-chloropropoxy)benzenecarbothioamide | 911134-67-3

中文名称
——
中文别名
——
英文名称
4-(3-chloropropoxy)benzenecarbothioamide
英文别名
——
4-(3-chloropropoxy)benzenecarbothioamide化学式
CAS
911134-67-3
化学式
C10H12ClNOS
mdl
——
分子量
229.73
InChiKey
FSFBVQAGJZPTTD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    67.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Phenyl-oxazoles, a New Family of Inverse Agonists at the H<sub>3</sub>Histamine Receptor
    作者:Frédéric Denonne、Franck Atienzar、Sylvain Célanire、Bernard Christophe、Frédérique Delannois、Christel Delaunoy、Marie-Laure Delporte、Véronique Durieu、Michel Gillard、Bénédicte Lallemand、Yves Lamberty、Geneviève Lorent、Alain Vanbellinghen、Nathalie Van houtvin、Valérie Verbois、Laurent Provins
    DOI:10.1002/cmdc.200900446
    日期:2010.2.1
    Drug design: Oxazoles and thiazoles were designed and synthesised based on previously reported ligands of the 3rd histamine receptor (H3R). The aminopropoxy‐phenyl‐oxazole chemotype was identified as a promising H3R inverse agonist with superior drug‐like properties, good efficacy in vivo and good safety margin.
    药物设计:恶唑和噻唑是基于先前报道的第三组胺受体(H 3 R)的配体设计和合成的。氨基丙氧基-苯基-恶唑的化学型被认为是一种有前途的H 3 R反向激动剂,具有出色的类药物特性,体内良好的疗效和良好的安全性。
  • Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
    申请人:Denonne Frédéric
    公开号:US20100009969A1
    公开(公告)日:2010-01-14
    The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H 3 -receptor ligands, wherein A is a cyclic amine which is linked to the propylene group via an amino nitrogen; B is selected from the group consisting of heteroaryl, 5-8-membered heterocycloalkyl, 5-8-membered cycloalkyl; X is either N or CH; Y is either O or S.
    本发明涉及公式(I)的融合噁唑或噻唑衍生物化合物,制备它们的方法,包含该化合物的制药组合物以及它们作为H3受体配体的用途,其中A是通过氨基氮与丙烯基团连接的环状胺基;B从异芳基,5-8成员杂环烷基,5-8成员环烷基的群组中选取;X为N或CH;Y为O或S。
  • Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses
    申请人:Celanire Sylvain
    公开号:US20080275046A1
    公开(公告)日:2008-11-06
    The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H 3 -receptor ligands, Formula (I), wherein, A 1 is CH, C(alkyl), C-halogen or N; R 1 is hydrogen, halogen, C 1-6 alkyl or alkoxy; R 2 is, Formula (II′), A 3 is O or S; R 3 is hydrogen, halogen, C 1-6 alkyl or alkoxy; R 4 is hydrogen, halogen, C 1-6 alkyl, alkoxy or —O-L; R 5 is hydrogen or —O-L, wherein L is an aminoalkyl group and at least one of R 4 and R 5 should be —O-L.
    本发明涉及一种包含氧唑或噻唑基团的化合物,其化学式为(I),以及制备它们的方法、包含该化合物的药物组合物以及其作为H3受体配体的用途,式(I)中,A1为CH、C(烷基)、C-卤或N;R1为氢、卤素、C1-6烷基或烷氧基;R2为式(II')、A3为O或S;R3为氢、卤素、C1-6烷基或烷氧基;R4为氢、卤素、C1-6烷基、烷氧基或-O-L;R5为氢或-O-L,其中L为氨基烷基团,且R4和R5中至少有一个应为-O-L。
  • Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
    申请人:UCB Pharma, S.A.
    公开号:US07790720B2
    公开(公告)日:2010-09-07
    The present invention relates to compounds comprising an oxazole or thiazole moiety of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, Formula (I), wherein, A1 is CH, C(alkyl), C-halogen or N; R1 is hydrogen, halogen, C1-6 alkyl or alkoxy; R2 is, Formula (II′), A3 is O or S; R3 is hydrogen, halogen, C1-6 alkyl or alkoxy; R4 is hydrogen, halogen, C1-6 alkyl, alkoxy or —O-L; R5 is hydrogen or —O-L, wherein L is an aminoalkyl group and at least one of R4 and R5 should be —O-L.
    本发明涉及一种包含氧唑或噻唑基团的化合物,其化学式为(I),以及制备它们的方法、包含所述化合物的制药组合物以及它们作为H3受体配体的用途,其中,A1为CH、C(烷基)、C-卤素或N;R1为氢、卤素、C1-6烷基或烷氧基;R2为化学式(II'),A3为O或S;R3为氢、卤素、C1-6烷基或烷氧基;R4为氢、卤素、C1-6烷基、烷氧基或-O-L;R5为氢或-O-L,其中L为氨基烷基团,且R4和R5中至少有一个应为-O-L。
  • WO2008/12010
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多